Evaluation of the most commonly used (semi-) quantitative parameters of 18F-FDG PET/CT to detect malignant transformation of neurofibromas in neurofibromatosis type 1

被引:12
作者
Brinkman, Marloes [1 ]
Jentjens, Sander [2 ,6 ]
Boone, Kitty [2 ]
Anten, Monique [1 ,3 ]
Stumpel, Constance T. R. M. [3 ,4 ]
Nelemans, Patty J. [5 ]
van Kroonenburgh, Marinus J. P. G. [2 ,3 ]
机构
[1] Maastricht Univ, Med Ctr, Dept Neurol, Maastricht, Netherlands
[2] Maastricht Univ, Med Ctr, Dept Radiol & Nucl Med, P Debyelaan 25, NL-6229 HX Maastricht, Netherlands
[3] Maastricht Univ, Med Ctr, Neurofibromatosis Expert Team, Maastricht, Netherlands
[4] Maastricht Univ, Med Ctr, Dept Clin Genet, Maastricht, Netherlands
[5] Maastricht Univ, Med Ctr, Dept Epidemiol, Maastricht, Netherlands
[6] Catharina Hosp, Dept Nucl Med, Eindhoven, Netherlands
关键词
malignant peripheral nerve sheath tumor; neurofibromatosis type 1; PET/CT; POSITRON-EMISSION-TOMOGRAPHY; NERVE SHEATH TUMORS; CEREBRAL GLUCOSE-METABOLISM; UPTAKE VALUE SUV; TO-LIVER RATIO; FDG-PET; SARCOMATOUS TRANSFORMATION; PLEXIFORM NEUROFIBROMAS; SOLITARY NEUROFIBROMA; COMPUTED-TOMOGRAPHY;
D O I
10.1097/MNM.0000000000000889
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
In patients with neurofibromatosis type 1, transformation of neurofibromas into a malignant peripheral nerve sheath tumor (MPNST) is a severe complication of the disease. Fluorine-18-fluorodeoxyglucose PET/computed tomography (PET/CT) is a viable option for detecting malignant tumors in neurofibromatosis type 1 patients. The aim of this review was to assess the diagnostic performance of the most frequently used parameters of PET/CT in detecting MPNST. An extensive computer search was performed using the Cochrane Library, Pubmed, and Medline/Embase databases. Two reviewers independently extracted data of relevant studies and assessed the methodological quality (QUADAS-2). The diagnostic performance of PET/CT parameters in individual studies was determined by calculating a diagnostic odds ratio (DOR) using the absolute numbers of true-positive, true-negative, false-positive, and false-negative test results. A total of eight studies were included, of which three evaluated the standardized uptake value as a diagnostic parameter, two assessed the tumor-to-liver (T/L) ratio, and three articles described both parameters. The cut-off values for maximum standardized uptake value (SUVmax) ranged from 3.2 to 4.5; for the T/L ratio, the cut-off values were between 1.0 and 4.3. The sensitivity and specificity ranged from 90 to 100% and from 80 to 100%, respectively (SUVmax). T/L ratios were associated with 92-100% sensitivity and 72-94% specificity. The corresponding DORs ranged from 57 to 145 (SUVmax) and 35 to 655 (T/L ratio). Both the SUV and the T/L ratio are associated with high sensitivity combined with acceptable specificity in detecting MPNST. There is a tendency toward higher DORs using the T/L ratio, but the number of studies is limited. Copyright (C) 2018 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:961 / 968
页数:8
相关论文
共 136 条
[1]   Schwannoma in neurofibromatosis type 1: a pitfall for detecting malignancy by metabolic imaging [J].
Ahlawat, Shivani ;
Blakeley, Jaishri ;
Montgomery, Elizabeth ;
Subramaniam, Rathan M. ;
Belzberg, Allan ;
Fayad, Laura M. .
SKELETAL RADIOLOGY, 2013, 42 (09) :1317-1322
[2]   Growth rate characteristics of acoustic neuromas associated with neurofibromatosis type 2 [J].
Abaza, MM ;
Makariou, E ;
Armstrong, M ;
Lalwani, AK .
LARYNGOSCOPE, 1996, 106 (06) :694-699
[3]   Cerebral glucose metabolism in adults with neurofibromatosis type 1 [J].
Apostolova, Ivayla ;
Derlin, Thorsten ;
Salamon, Johannes ;
Amthauer, Holger ;
Granstroem, Sofia ;
Brenner, Winfried ;
Mautner, Victor-Felix ;
Buchert, Ralph .
BRAIN RESEARCH, 2015, 1625 :97-101
[4]   Perfusion single photon emission computed tomography in a mouse model of neurofibromatosis type 1: towards a biomarker of neurologic deficits [J].
Apostolova, Ivayla ;
Niedzielska, Dagmara ;
Derlin, Thorsten ;
Koziolek, Eva J. ;
Amthauer, Holger ;
Salmen, Benedikt ;
Pahnke, Jens ;
Brenner, Winfried ;
Mautner, Victor F. ;
Buchert, Ralph .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2015, 35 (08) :1304-1312
[5]   18F-FDG-PET imaging of a benign neurofibroma masquerading as metastatic oesophageal carcinoma [J].
Azad, A. ;
Chong, G. ;
Tauro, A. ;
Aly, A. ;
Tebbutt, N. C. .
MEDICAL ONCOLOGY, 2010, 27 (02) :230-232
[6]   CEREBRAL GLUCOSE-METABOLISM IN NEUROFIBROMATOSIS TYPE-1 ASSESSED WITH [F-18] 2-FLUORO-2-DEOXY-D-GLUCOSE AND PET [J].
BALESTRI, P ;
LUCIGNANI, G ;
FOIS, A ;
MAGLIANI, L ;
CALISTRI, L ;
GRANA, C ;
DIBARTOLO, RM ;
PERANI, D ;
FAZIO, F .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1994, 57 (12) :1479-1483
[7]   Potential clinical role of FDG-PET in detecting sarcomatous transformation in von Recklinghausen's Disease: a case study and review of the literature [J].
Basu, Sandip ;
Nair, Narendra .
JOURNAL OF NEURO-ONCOLOGY, 2006, 80 (01) :91-95
[8]   Atypical Neurofibromas in Neurofibromatosis Type 1 are Premalignant Tumors [J].
Beert, Eline ;
Brems, Hilde ;
Daniels, Bruno ;
De Wever, Ivo ;
Van Calenbergh, Frank ;
Schoenaers, Joseph ;
Debiec-Rychter, Maria ;
Gevaert, Olivier ;
De Raedt, Thomas ;
Van den Bruel, Annick ;
de Ravel, Thomy ;
Cichowski, Karen ;
Kluwe, Lan ;
Mautner, Victor ;
Sciot, Raf ;
Legius, Eric .
GENES CHROMOSOMES & CANCER, 2011, 50 (12) :1021-1032
[9]   Utility of 18 FDG positon emission tomography in detection of sarcomatous transformation in neurofibromatosis type I [J].
Bensaid, B. ;
Giammarile, F. ;
Mognetti, T. ;
Galoisy-Guibal, L. ;
Pinson, S. ;
Drouet, A. ;
Combemale, P. .
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2007, 134 (10) :735-741
[10]   Quantitative F18-Fluorodeoxyglucose Positron Emission Tomography Accurately Characterizes Peripheral Nerve Sheath Tumors as Malignant or Benign [J].
Benz, Matthias R. ;
Czernin, Johannes ;
Dry, Sarah M. ;
Tap, William D. ;
Allen-Auerbach, Martin S. ;
Elashoff, David ;
Phelps, Michael E. ;
Weber, Wolfgang A. ;
Eilber, Fritz C. .
CANCER, 2010, 116 (02) :451-458